Log In
Print
BCIQ
Print
Print this Print this
 

antimiR-208 (miR-208)

  Manage Alerts
Collapse Summary General Information
Company miRagen Therapeutics Inc.
DescriptionModified short nucleic acid sequence targeting microRNA-208
Molecular Target MicroRNA-208 (miR-208)
Mechanism of Action 
Therapeutic ModalityNucleic acid: Linear RNA: microRNA
Latest Stage of DevelopmentPreclinical
Standard IndicationHeart failure
Indication DetailsTreat chronic heart failure (CHF)
Regulatory Designation

Partner

Servier


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today